Write a 4- to 6-page paper, not including cover and reference page, in which, after again reviewing and analyzing the results that you got in SLP2 (Time Warp 1 decisions), you develop a revised strategy and make a case for this new strategy using analysis and relevant theories.
KEYS TO THE ASSIGNMENT
The key aspects of this assignment that should be covered and taken into account in preparing your paper include:
The revised strategy consists of the Prices, Research and Development (R&D) Allocation %, and any product discontinuations for the X5, X6, and X7 tablets for each of the four years: 2012, 2013, 2014, and 2015.
You must present a rational justification for this strategy. In other words, you must make a case for your proposed strategy using financial analysis and relevant theories.
Use the CVP Calculator and review the PowerPoint that explains CVP and provides some examples.
You need to crunch some numbers (CVP Analysis) to help you determine your prices and R&D allocations.
Present your analysis professionally making strategic use of tables, charts and graphs.
Time Line Summary:
2015: Hired on December 15.
Turned in first report to Sally a few days early on December 30.
Celebrated on December 31.
Time Warp 1 begins: January 1, 2016 warps into January 1, 2012.
You realize you have to make decisions for 2012 - 2015, which you do.
December 31, 2015 - You have gone through all four years, and you write your report to summarize how you did. You are hoping that you will wake up tomorrow and it will be 2016.
Time Warp 2 begins: January 1, 2016 warps into January 1, 2012. (Again)
Now it is January 1, 2012: You decide to use CVP analysis and develop a four-year plan for your strategy. You analyze the results of your first decisions in Time Warp 1 and make notes. You use the CVP Calculator to help develop a strategy, and make more notes explaining your logic and analysis.
This solution explains the use of cost value profit analysis to determine research and development allocation. The sources used are also included in the solution.